Cargando…

Strengthening the case that elevated levels of programmed death ligand 1 predict poor prognosis in hepatocellular carcinoma patients

Immunotherapy targeting programmed death receptor 1 and programmed death ligand 1 (PD-L1) has shown impressive antitumor efficacy in several solid cancers, including advanced hepatocellular carcinoma (HCC). Since response rates of various cancers to such immunotherapy appear to correlate with PD-L1...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhong, Jian-Hong, Luo, Cheng-Piao, Zhang, Chun-Yan, Li, Le-Qun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2016
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5221808/ https://www.ncbi.nlm.nih.gov/pubmed/28116284 http://dx.doi.org/10.2147/JHC.S122807

Ejemplares similares

Increased programmed death ligand-1 expression predicts poor prognosis in hepatocellular carcinoma patients
por: Gu, Xiaobin, et al.
Publicado: (2016)

Expression patterns of programmed death ligand 1 correlate with different microenvironments and patient prognosis in hepatocellular carcinoma
por: Liu, Chao-Qun, et al.
Publicado: (2018)

Elevated serum visfatin levels are associated with poor prognosis of hepatocellular carcinoma
por: Sun, Yifan, et al.
Publicado: (2017)

High Soluble Programmed Death-Ligand 1 Predicts Poor Prognosis in Patients with Nasopharyngeal Carcinoma
por: Lu, Tianzhu, et al.
Publicado: (2020)

High Serum Level of Soluble Programmed Death Ligand 1 is Associated With a Poor Prognosis in Hodgkin Lymphoma
por: Guo, Xiaofang, et al.
Publicado: (2018)

Protein expression of programmed death 1 ligand 1 and ligand 2 independently predict poor prognosis in surgically resected lung adenocarcinoma
por: Zhang, Yang, et al.
Publicado: (2014)

Elevated expression of Cripto-1 correlates with poor prognosis in hepatocellular carcinoma
por: Wang, Jia-hong, et al.
Publicado: (2015)

A new resource for developing and strengthening large-scale community health worker programs
por: Perry, Henry, et al.
Publicado: (2017)

Elevated STIL predicts poor prognosis in patients with hepatocellular carcinoma
por: Song, Huangqin, et al.
Publicado: (2023)

Elevated serum soluble programmed cell death ligand 1 concentration as a potential marker for poor prognosis in small cell lung cancer patients with chemotherapy
por: Jin, Jianjun, et al.
Publicado: (2018)

Programmed death-ligand 1 expression correlates with diminished CD8+ T cell infiltration and predicts poor prognosis in anal squamous cell carcinoma patients
por: Zhao, Yu-Jie, et al.
Publicado: (2017)

Programmed cell death ligand 1 expression in a case of poorly differentiated lymphocyte‐rich hepatocellular carcinoma
por: Omori, Ginji, et al.
Publicado: (2021)

Becoming FASD Informed: Strengthening Practice and Programs Working with Women with FASD
por: Rutman, Deborah
Publicado: (2016)

High post-treatment serum levels of soluble programmed cell death ligand 1 predict early relapse and poor prognosis in extranodal NK/T cell lymphoma patients
por: Wang, Hua, et al.
Publicado: (2016)

Commentary on “Clinicopathological features of programmed cell death-ligand 1 expression in patients with oral squamous cell carcinoma”
por: Peña-Cardelles, Juan Francisco, et al.
Publicado: (2022)

Expression of programmed death ligand-1 predicts poor outcome in nasopharyngeal carcinoma
por: Li, Ying-Fei, et al.
Publicado: (2017)

Overexpression of Epcam and CD133 Correlates with Poor Prognosis in Dual-phenotype Hepatocellular Carcinoma
por: Zhang, Jie, et al.
Publicado: (2020)

Strengthening Health Systems for Climate Adaptation and Health Security: Key Considerations for Policy and Programming
por: Lugten, Elizabeth, et al.
Publicado: (2022)

Elevated apolipoprotein B predicts poor postsurgery prognosis in patients with hepatocellular carcinoma
por: Yan, Xiaotong, et al.
Publicado: (2019)

Programmed death ligand-1/programmed death-1 inhibition therapy and programmed death ligand-1 expression in urothelial bladder carcinoma
por: Yu, Wei-Bo, et al.
Publicado: (2019)

Programmed death-ligand 1 expression in the tumour stroma of colorectal liver oligometastases and its association with prognosis after liver resection
por: Peng, Jian-Hong, et al.
Publicado: (2020)

Programmed Death Ligand 1: A Poor Prognostic Marker in Endometrial Carcinoma
por: Chew, Mianxin, et al.
Publicado: (2020)

Programmed Cell Death Protein 1/Programmed Cell Death Ligand-1 Axis activates Intracellular ERK Signaling in Tumor Cells to Mediate Poor Prognosis in T-cell Lymphoma
por: Li, Yang, et al.
Publicado: (2021)

Elevated levels of serum urokinase plasminogen activator predict poor prognosis in hepatocellular carcinoma after resection
por: Tsai, Ming-Chao, et al.
Publicado: (2019)

First-line pembrolizumab in programmed death ligand 1 positive non-small cell lung cancer
por: Travert, Camille, et al.
Publicado: (2019)

Lenvatinib/Pembrolizumab as second line treatment for advanced melanoma patients refractory to programmed death 1 (PD-1)/programmed death ligand-1 (PD-L1) inhibitors
por: Ferrucci, Pier Francesco
Publicado: (2023)

Elevated Expression of PDZD11 Is Associated With Poor Prognosis and Immune Infiltrates in Hepatocellular Carcinoma
por: Chen, Yao, et al.
Publicado: (2021)

Elevated NDC1 expression predicts poor prognosis and correlates with immunity in hepatocellular carcinoma
por: Liu, Qingqing, et al.
Publicado: (2023)

Positive Expression of Programmed Death Ligand 1 in Peritumoral Liver Tissue is Associated with Poor Survival after Curative Resection of Hepatocellular Carcinoma()
por: Dai, Xiaomeng, et al.
Publicado: (2017)

Strengthening Brain Research in Africa
por: Aborode, Abdullahi Tunde, et al.
Publicado: (2023)

Elevated Small Nuclear Ribonucleoprotein Polypeptide an Expression Correlated With Poor Prognosis and Immune Infiltrates in Patients With Hepatocellular Carcinoma
por: Zhang, Youfu, et al.
Publicado: (2022)

NSUN5 promotes progression and predicts poor prognosis in hepatocellular carcinoma
por: Zhang, Xiao-Wen, et al.
Publicado: (2022)

Programmed Death Ligand 1 Expression in Laryngeal Squamous Cell Carcinomas and Prognosis
por: Batur, Sebnem, et al.
Publicado: (2020)

Expression of Programmed Death Ligand-2 is associated with Prognosis in Nasopharyngeal Carcinoma Microenviroment
por: Li, Aixin, et al.
Publicado: (2022)

How has the Ascend programme contributed to strengthening health systems for sustainable country-driven neglected tropical disease programming?
por: Rowan, Sinead, et al.
Publicado: (2022)

Commentary: Ophthalmology training programs: Optimization of human resource to supplement clinical expertise and strengthen eye care delivery systems
por: Singh, Priti, et al.
Publicado: (2023)

Cities as an Enabler for Strengthening Cancer Care
por: Henshall, Susan, et al.
Publicado: (2021)

Programmed death‐ligand 1 expression at tumor invasive front is associated with epithelial‐mesenchymal transition and poor prognosis in esophageal squamous cell carcinoma
por: Tsutsumi, Satoshi, et al.
Publicado: (2017)

Programmed Death-Ligand 1 (PD-L1) Positivity and Factors Associated with Poor Prognosis in Patients with Gastric Cancer: An Umbrella Meta-Analysis
por: Hassen, Gashaw, et al.
Publicado: (2022)

Until programmed death do us tolerant
por: Scott, David W.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_cu6088qnn6gsnvom1d5g1ra4pn